Dialkyl phenyl phosphates as novel selective inhibitors of butyrylcholinesterase

Biochemical and Biophysical Research Communications

Volumn 355, Issue 2, 2007, Pages 371-378

  Law, Ken Shing ^a   Acey, Roger A ^a   Smith, Cameron R ^a   Benton, David A ^a   Soroushian, Sheila ^a   Eckenrod, Brett ^b   Stedman, Rachael ^b   Kantardjieff, Katherine A ^b   Nakayama, Kensaku ^a  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

Acetylcholinesterase; Alzheimer's; Butyrylcholinesterase

Indexed keywords

CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DI CYCLOHEXYLPHENYL PHOSPHATE; DI N BUTYLPHENYL PHOSPHATE; DI N PENTYLPHENYL PHOSPHATE; DI N PROPYLPHENYL PHOSPHATE; DIETHYLPHENYL PHOSPHATE; DIMETHYLPHENYL PHOSPHATE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL STRUCTURE; CHOLINESTERASE INHIBITION; COMPETITIVE INHIBITION; DEMENTIA; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SYNTHESIS;

BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; ORGANOPHOSPHORUS COMPOUNDS;

EID: 33847220716     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.01.186     Document Type: Article

References (42)

1. Patocka J. Acetylcholinesterase inhibitors-from nervuous gas to Alzheimer's disease therapeutics. Chem. Listy 92 (1998) 1016-1019
2. Giacobini E. Cholinergic function and Alzheimer's disease. Int. J. Geriatr. Psych. 18 (2003) S1-S5
3. Arendt T., Bruckner M.K., Lange M., and Bigl V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development-a study of molecular forms. Neurochem. Int. 21 (1992) 381-396
4. Perry E.K., H P.P., G B., and Tomlinson B.E. Changes in brain cholinesterases in senile dementia of Alzheimer's disease. Neuropathol. Appl. Neurobiol. 4 (1978) 273-277
5. Taylor P. The cholinesterases. J. Biol. Chem. 266 (1991) 4025-4028
6. Bartus R.T., Dean L.D.I., Beer B., and Lippa A.S. The cholinergis hypothesis of geriatric memory dysfunction. Science 217 (1982) 408-417
7. Giacobini E. Acetyl- and butyrylcholinesterase inhibition by rivastigmine in cerebrospinal fluid of patients with Alzheimer's disease correates with cognitive benefit. J. Neural Transm. 109 (2002) 1053-1065
8. Grossberg T. Cholinesterase inhibitors for the treatment of Alzheimer's disease: getting on and stayng on. Curr. Ther. Res. 64 (2003) 216-235
9. Giacobini E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmaco. Res. 50 (2004) 433-440
10. Greig N.H., Utsuki T., Yu Q., Zhu X., Hollaway H., Perry T., Lee B., Ingram D.K., and Lahiri D.K. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr. Med. Res. Opin. 17 (2001) 159-165
11. Giacobini E. Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy. In: Giacobini E. (Ed). Cholinesterase and Cholinesterase Inhibitors (2000), Martin Dunitz, London 181-226
12. Andreeva A., Howorth D., Brenner S.E., Hubbard T.J.P., Chothia C., and Murzin A.G. SCOP database in 2004: refinements integrate structure and sequence family data. Nucleic Acids Res. 32 (2004) D226-D229
13. Kryger G., Harel M., Giles K., Toker L., Velan B., Lazar A., Kronman C., Barak D., Ariel N., Shafferman A., Silman I., and Sussman J.L. Structures of recombinant wild-type human acetylcholinesterase and of its E202Q mutant as complexes with fasciculin-II, a 'three-finger' polypeptide. Acta Crystallogr. D 56 (2000) 1385-1394
14. Nicolet Y., Lockridge O., Masson P., Fontecilla-Camps J.C., and Nachon F. Crystal structure of human butyrylcholinesterase and of its complexes with substrates and products. J. Biol. Chem. 278 (2003) 41141-41147
15. Atack J.R., Perry E.K., Bonham J.R., Candy J.M., and Perry R.H. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J. Neurochem. 47 (1986) 263-277
16. Atack J.R., Perry E.K., Bonham J.R., Candy J.M., and Perry R.H. Molecular forms of butyrylcholinesterase in the human neocortex during development and degeneration of the cortical cholinergic system. J. Neurochem. 48 (1987) 1687-1692
17. Atack J.R., Perry E.K., Bonham J.R., and Perry R.H. Molecular forms of acetylcholinesterase and butyrylcholinesterase in human plasma and cerebrospinal fuid. J. Neurochem. 48 (1987) 1845-1850
18. Moral-Naranjo M.T., Cabezas-Herrara J., and Vidal C.J. Molecular forms of acetyl- and butyrylcholinesterase in normal and dystrophic mouse brain. J. Neurosci. Res. 43 (1996) 224-234
19. Nese Cokugras A. Butyrylcholinesterase: structure and physiological important. Turk. J. Biochem. 28 (2003) 54-61
20. Harel M., Schalk I., Ehret-Sabatier L., Bouet F., Goeldner M., Hirth C., Axelsen P.H., Silman I., and Sussman J.L. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc. Natl. Acad. Sci. USA 90 (1993) 9031-9035
21. Bourne Y., Taylor P., Radic Z., and Marchot P. Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site. EMBO J. 22 (2003) 1-12
22. Fukuto T.R., and Metcalf R.L. Structure and insecticidal activity of some diethyl substituted phenyl phosphates. J. Agric. Food Chem. 4 (1956) 930-935
23. Raushel F.M., and Hong S.-B. Stereochemical constraints on the substrate specificity of phosphotriesterase. Biochemistry 38 (1999) 1159-1165
24. Zhang N.J., and Casida J.E. Novel irreversible butyrylcholinesterase inhibitors: 2-chloro-1-(substituted-phenyl)ethylphosphonic acids. Bioorg. Med. Chem. 10 (2002) 1281-1290
25. Doorn J.A., Talley T.T., Thompson C.M., and Richardson R.J. Probing the active sites of burytylcholinesterase and cholesterol esterase with isomalathion: conserved stereoselective inactivation of serine hydrolases structurally related to acetylcholinesterase. Chem. Res. Toxicol. 14 (2001) 807-813
26. Yu Q.-S., Hollaway H.W., Utsuki T., Brossi A., and Greig N.H. Synthesis of novel phenserine-based selective inhibitors of butyrylcholinesterase for Alzheimer's disease. J. Med. Chem. 42 (1999) 1855-1861
27. Farlow M.R., and Cyrus P.A. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials. Dement. Geriatr. Cogn. Disord. 11 (2000) 202-211
28. Ellman G.L., Courney K.D., Jr A.V., and Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7 (1961) 88-95
29. In: Segel I.H. (Ed). Enzyme k-Kinetics (1975), John Wiley, Toronto
30. Schapira M., Abagyan R., and Totrov M. Nuclear hormone receptor targeted virtual screening. J. Med. Chem. 46 (2003) 3045-3059
31. Schapira M., Raaka B.M., Das S., Fan L., Totrov M., Zhou Z., Wilson S.R., Abagyan R., and Samuels H.H. Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking. Proc. Nat. Acad. Sci. USA 100 (2003) 7354-7359
32. An J., Totrov M., and Abagyan R. Pocketome via comprehensive identification and classification of ligand binding envelopes. Mol. Cell Proteomics 4 (2005) 752-761
33. Hooft R.R.W., Vriend G., Sander C., and Albola E.E. Errors in protein structures. Nature 381 (1996) 272
34. Kleywegt G.J., and Jones A.T. Phi/Psi-chology: Ramachandran revisited. Structure 4 (1996) 1395-1400
35. Laskowski R.A., MacArthur M.W., Moss D.S., and Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Cryst. 26 (1993) 283-291
36. Lovell S.C., Davis I.W., Arendall III W.B., de Bakker P.I., Word J.M., Prisant M.G., Richardson J.S., and Richardson D.C. Structure validation by C-alpha geometry: phi, psi and C-beta deviation. Proteins 50 (2003) 437-450
37. Maiorov V., and Abagyan R. Energy strain in three-dimensional protein structures. Fold. Des. 3 (1998) 259-269
38. Sippl M.J. Recognition of errors in three-dimensional structures of proteins. Proteins 17 (1993) 355-362
39. Guo J.X., Wu J.J., Wright J.B., and Lushington G.H. Mechanistic insight into acetylcholinesterase inhibition and acute toxicity of organophosphorous compounds: a molecular modeling study. Chem. Res. Toxicol. 19 (2006) 209-216
40. Johnson G., and Moore S.W. The peripheral anionic site of acetylcholinesterase: structure, functions and potential role in rational drug design. Curr. Pharm. Des. 12 (2006) 217-225
41. Campiani G., Fattorusso C., Butini S., Gaeta A., Agnusdei M., Gemma S., Persico M., Catalanotti B., Savini L., Nacci V., Novellino E., Hollaway H.W., Greig N.H., Belinskaya T., Fedorko J.M., and Saxena A. Development of molecular probes for the identification of extra sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors. J. Med. Chem. 48 (2005) 1919-1929
42. Gerula C., and Mesulam M.M. Cholinesterase and the pathology of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 9 (1995) 23-28